The World Health Organization's Policy Advisory Team of Specialists on Immunization (SAGE) has modified interim guidelines for the use of Moderna COVID-19 (mRNA-1273) vaccine for COVID-19. The interim suggestions are summarised in this section.
Health professionals with increased risk of exposure and the elderly, like with all COVID-19 vaccines, should be vaccinated first.
Additional prioritized groups should be immunized as more vaccines become accessible, with a focus on persons who are disproportionately impacted by COVID-19 or who confront healthcare disparities.
Chronic Lung Illness, Major Heart Disease, Severe Obesity, Diabetes, Liver Disease, And Immune Deficiency Virus (Hiv) Infections Were Among The Comorbidities Investigated In The Phase 3 Trial. Vaccination Is Advised For People Who Have Illnesses That Have Been Linked To A Higher Risk Of Serious Covid-19 Infection.
People who are compromised, such as those living with HIV, are at an increased risk of developing severe COVID-19 disease. An additional dosage (third dose) is advised as part of the main vaccine series, 1-3 months after the two doses, because the immunological responses in such people is diminished. Vaccine patients who are known to be HIV positive should be provided information and counselling.
People who have already been exposed to COVID-19 can be vaccinated. Persons may prefer to postpone their COVID-19 immunisation for up to six months after contracting SARS-CoV-2.
Vaccine efficiency in breastfeeding mothers is likely to be similar to that in other adults. The vaccine should be given to breastfeeding women as well as other people, according to the WHO. Breastfeeding should not be stopped due to vaccination, according to the World Health Organization.
The Moderna vaccine was found to be well absorbed, immunogenic, and effective in a phase 3 trial in adolescents aged 12–17 years.
The vaccination should be administered in two doses (100 g, 0.5 ml each) 8 weeks apart, according to the WHO.
WHO recommends that nations use the vaccine in children aged 12 to 17 years old only after achieving high vaccination coverage with two doses in the high priority categories defined in the WHO Prioritization Roadmap.
Children and adolescents aged 12-17 years old with comorbidity who are at a much increased risk of major COVID-19 disease, as well as other elevated categories, should be provided vaccination.
The vaccine's safety and effectiveness in children under the age of 12 are still being studied.
Moderna requested urgent use authorisation from the Food & Drug Administration on Thursday for a fourth dosage of its COVID-19 vaccine as a booster for people aged 18 and up, a demand that was broader than Pfizer's request a few days ago.
A single booster dosage of Moderna's mRNA vaccine, in addition to the two-dose vaccine, is currently approved for emergency use.
The biotech firm's proposal comes just two days after Pfizer and its collaboration BioNTech asked the FDA for approval to just provide adults 65 and older an extra booster dosage of its COVID-19 vaccine Comirnaty.
Moderna said it sought approval for all people "to give the Centers for Disease Control and Prevention and medical providers freedom" in determining the "appropriate use" of a second drug.
In accordance with the WHO Prioritization Roadmap, a higher dose may be contemplated 4–6 months following completion of the first vaccine series, albeit this is primarily advised for the greater priority groups.
The booster dose should be half the dosage used in the first vaccine series (50 g at 0.25 ml), according to the WHO.
Following growing evidence of diminishing vaccine effectiveness against mild and symptomatic SARS-CoV-2 infection over time, the advantages of booster immunisation are becoming recognised.
Moderna's appeal for emergency use clearance is partly based on previously published data from the United States and Israel in the aftermath of the appearance of the omicron form, according to the company.
The business did not say what the data from the United States and Israel revealed, but Israel authorized a fourth COVID vaccine dose for vulnerable persons over the age of 18 in January 2022. Furthermore, a study of over 1 million Israelis over the age of 60 found that individuals who received a fourth dosage of the Pfizer-BioNTech vaccine were half as likely to become infected and four times less likely to become critically ill than those who received only three doses. That research was not peer-reviewed.
Other studies have found that the efficacy of mRNA vaccines like Pfizer's and Moderna's begins to wane after the third injection, roughly three months later.
According to data from the Centers for Disease and Prevention, approximately 216 million Americans – or 65.2 percent of people – were completely vaccinated as of March 2022, with 44.4 percent receiving a higher dose.